NO994750L - Anti-Fas-antistoffer - Google Patents

Anti-Fas-antistoffer

Info

Publication number
NO994750L
NO994750L NO994750A NO994750A NO994750L NO 994750 L NO994750 L NO 994750L NO 994750 A NO994750 A NO 994750A NO 994750 A NO994750 A NO 994750A NO 994750 L NO994750 L NO 994750L
Authority
NO
Norway
Prior art keywords
fas
fas antibodies
antibodies
abnormalities
mouse
Prior art date
Application number
NO994750A
Other languages
English (en)
Norwegian (no)
Other versions
NO994750D0 (no
Inventor
Nobufusa Serizawa
Hideyuki Haruyama
Kaori Nakahara
Ikuko Tamaki
Tohru Takahashi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO994750D0 publication Critical patent/NO994750D0/no
Publication of NO994750L publication Critical patent/NO994750L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO994750A 1998-09-30 1999-09-29 Anti-Fas-antistoffer NO994750L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27688298 1998-09-30
JP27688198 1998-09-30

Publications (2)

Publication Number Publication Date
NO994750D0 NO994750D0 (no) 1999-09-29
NO994750L true NO994750L (no) 2000-03-31

Family

ID=26552152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994750A NO994750L (no) 1998-09-30 1999-09-29 Anti-Fas-antistoffer

Country Status (14)

Country Link
EP (1) EP0990663A3 (xx)
KR (1) KR20000023549A (xx)
CN (1) CN1266714A (xx)
AR (1) AR023333A1 (xx)
AU (1) AU757961B2 (xx)
BR (1) BR9904475A (xx)
CA (1) CA2283540A1 (xx)
HU (1) HUP9903299A3 (xx)
ID (1) ID25978A (xx)
IL (1) IL132139A0 (xx)
NO (1) NO994750L (xx)
NZ (1) NZ500019A (xx)
PL (1) PL335752A1 (xx)
RU (1) RU2223115C2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065935A2 (en) 1998-06-18 1999-12-23 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
JP4907843B2 (ja) * 2002-03-25 2012-04-04 公益財団法人ひろしま産業振興機構 ヒト肝細胞増殖方法とヒト肝細胞の取得方法
NZ550816A (en) * 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2007255384B2 (en) * 2006-06-06 2012-09-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
KR20090088932A (ko) * 2006-12-06 2009-08-20 메디뮨 엘엘씨 전신 홍반성 낭창의 치료 방법
CA2710775A1 (en) * 2007-12-28 2009-07-09 Bioinvent International Ab Formulation
CN103408663B (zh) * 2008-10-31 2016-01-27 东丽株式会社 抗人cxcl1单克隆抗体或其片段
DK2186829T3 (en) * 2008-11-14 2015-04-07 Canadian Blood Services Antibodies to GPIbalfa
RU2519196C2 (ru) * 2011-07-01 2014-06-10 Олег Ильич Эпштейн Лекарственное средство для лечения патологического синдрома и способ лечения рассеянного склероза
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗mcam抗體及相關使用方法
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CA2938931A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
IL314725A (en) * 2015-10-23 2024-10-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody/T-cell receptor chimeric structures and their uses
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术(上海)有限公司 抗tigit的抗体、其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies

Also Published As

Publication number Publication date
EP0990663A2 (en) 2000-04-05
HUP9903299A3 (en) 2004-05-28
EP0990663A3 (en) 2002-04-17
HUP9903299A2 (hu) 2000-11-28
CN1266714A (zh) 2000-09-20
BR9904475A (pt) 2000-12-12
CA2283540A1 (en) 2000-03-30
NO994750D0 (no) 1999-09-29
KR20000023549A (ko) 2000-04-25
RU2223115C2 (ru) 2004-02-10
PL335752A1 (en) 2000-04-10
ID25978A (id) 2000-11-16
AU5016199A (en) 2000-04-13
AR023333A1 (es) 2002-09-04
NZ500019A (en) 2001-06-29
IL132139A0 (en) 2001-03-19
HU9903299D0 (en) 1999-11-29
AU757961B2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
NO994750L (no) Anti-Fas-antistoffer
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
SG2011076551A (en) Antibodies to opgl
ATE251942T1 (de) Stapelbare statische mischelemente
ATE212218T1 (de) Topische zusammensetzungen mit verbessertem hautgefühl
GR3026219T3 (en) Mouse monoclonal antibodies
ATE413386T1 (de) Ppar-gamma modulatoren
DE69330294D1 (de) Inter-hierarchisches Synchronisationssystem und LSI, das dieses System verwendet
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
NO20005692D0 (no) Forbedringer i og vedrörende bygningselementer, og fremgangsmåter vedrörende samme
FI965250A0 (fi) Noggrann maetning av koncentration foer en gaskomponent i en gasblandning, i vilken andra komponenter paoverkar koncentrationsbestaemningen
NO881051D0 (no) Metoder for behandling av solskadet, human hud med retinoider.
ID28441A (id) Terapi untuk memperbaiki kesadaran
NO981454D0 (no) Anti-FAS-antistoffer
ID29614A (id) Metoda penyekatan, aparatus untuk mengatur rapatan aliran cahaya dan aparatus untuk mengatur penyaluran sinar
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
PT1092040E (pt) Metodos de inibicao helicobacter pylori
DK1054691T3 (da) Antienzym-antistoffer til behandling af huden
ATE189897T1 (de) Antikörper gegen das prorenin profragment, reninaktive substanz die diese enthält und prorenintest die diese verwendet
DE3482924D1 (de) Reagenz zur verwendung im nachweis des antikoerpers gegen menschliche t-zellen-leukemievirusantigene.
ITRM930818A0 (it) Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
TR199902410A2 (xx) Anti-Fas Antikorları
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
WO1999038500A3 (en) The human calcium-sensing receptor in the detection and treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application